FDA reverses itself and will review Moderna mRNA flu vaccine
On February 10, 2026, the FDA denied Moderna’s biologics license application for its mRNA flu vaccine, citing insufficient trial data. After a meeting with Moderna on February 18, the FDA agreed to review a revised application, aiming for potential approval… Read More »FDA reverses itself and will review Moderna mRNA flu vaccine




